title: Ovarian cancer, version 3.2012.
abstract: These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.
authors.affiliation: City of Hope Comprehensive Cancer Center.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Morgan
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
authors.forename: Deborah K
authors.initials: DK
authors.lastname: Armstrong
authors.forename: Robert A
authors.initials: RA
authors.lastname: Burger
authors.forename: Mariana
authors.initials: M
authors.lastname: Castells
authors.forename: Lee-may
authors.initials: LM
authors.lastname: Chen
authors.forename: Larry
authors.initials: L
authors.lastname: Copeland
authors.forename: Marta Ann
authors.initials: MA
authors.lastname: Crispens
authors.forename: David
authors.initials: D
authors.lastname: Gershenson
authors.forename: Heidi
authors.initials: H
authors.lastname: Gray
authors.forename: Ardeshir
authors.initials: A
authors.lastname: Hakam
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Havrilesky
authors.forename: Carolyn
authors.initials: C
authors.lastname: Johnston
authors.forename: Shashikant
authors.initials: S
authors.lastname: Lele
authors.forename: Lainie
authors.initials: L
authors.lastname: Martin
authors.forename: Ursula A
authors.initials: UA
authors.lastname: Matulonis
authors.forename: David M
authors.initials: DM
authors.lastname: O'Malley
authors.forename: Richard T
authors.initials: RT
authors.lastname: Penson
authors.forename: Steven W
authors.initials: SW
authors.lastname: Remmenga
authors.forename: Paul
authors.initials: P
authors.lastname: Sabbatini
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Santoso
authors.forename: Russell J
authors.initials: RJ
authors.lastname: Schilder
authors.forename: Julian
authors.initials: J
authors.lastname: Schink
authors.forename: Nelson
authors.initials: N
authors.lastname: Teng
authors.forename: Theresa L
authors.initials: TL
authors.lastname: Werner
authors.forename: Miranda
authors.initials: M
authors.lastname: Hughes
authors.forename: Mary A
authors.initials: MA
authors.lastname: Dwyer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000628:therapy*